Epilepsy and bipolar disorders

Expert Review of Neurotherapeutics

Volumn 10, Issue 1, 2010, Pages 13-23

  Mula, Marco ^a   Marotta, Antonella Ester ^a   Monaco, Francesco ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Antidepressants; Antiepileptics; Antipsychotics; Bipolar disorder; Depression; Epilepsy; Lithium; Mania; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ION CHANNEL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OXCARBAZEPINE; VALPROIC ACID;

ANXIETY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR II DISORDER; COMORBIDITY; DEPRESSION; DISEASE COURSE; DYSPHORIA; ELECTROCONVULSIVE THERAPY; EPILEPSY; HUMAN; IRRITABILITY; KINDLING; MAINTENANCE THERAPY; MANIA; MOOD DISORDER; PATHOPHYSIOLOGY; REVIEW; SEDATION; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN;

ANTICONVULSANTS; BIPOLAR DISORDER; COMORBIDITY; EPILEPSY; HUMANS; ION CHANNELS; MODELS, BIOLOGICAL; NEUROTRANSMITTER AGENTS;

EID: 74949110590     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.09.139     Document Type: Review

References (103)

1. Lewis A. Melancholia: a historical review. J. Mental Sci. 80, 1-42 (1934).
2. Temkin O. The Falling Sickness: a History of Epilepsy from the Greeks to the Beginnings of Modern Neurology. John Hopkins University Press, Baltimore, MD USA (1971).
3. Kanner AM, Balabanov A. Depression and epilepsy: how closely related are they? Neurology 58(8 Suppl. 5), S27-S39 (2002).
4. Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res. 39(2), 121-125 (2000).
5. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555-567 (2007). • Review paper specifically dedicated to depression as an antiepileptic drug treatment-emergent adverse event.
6. Wolf P. Manic episodes in epilepsy. In: Advances in Epileptology: 13th Epilepsy International Symposium. Akimoto H, Kazamatsuri H, Seino M, Ward AA Jr (Eds). Raven Press, New York, USA 237-240 (1982).
7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition, Text Revision). American Psychiatric Association, Washington, DC, USA (2000).
8. Ettinger AB, Reed ML, Goldberg JF, Hirschfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 65, 535-540 (2005).
9. Mula M, Jauch R, Cavanna A et al. Psychopathological features of the so-called interictal dysphoric disorder of epilepsy. Epilepsia 49(6), 650-656 (2008). • The only available study investigating the clinical and psychopathological features of the so-called interictal dysphoric disorder of epilepsy.
10. Mazza M, Della Marca G, Di Nicola M et al. Oxcarbazepine improves mood in patients with epilepsy Epilepsy Behav. 10(3), 397-401 (2007).
11. Angst J, A, Benazzi, F, Ajdacic V, Eich D, Rössler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J. Affect. Disord. 73, 133-146 (2003).
12. Judd L, Akiskal H S. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J. Affect. Disord. 73, 123-131 (2003).
13. Goodwin FK, Jamison K. Manic-Depressive Illness, 2nd Edition. Oxford University Press, NY, USA (2007).
14. Sadler MJ. Falret's discovery: the origin of the concept of bipolar affective illness. Sedler MJ, Dessain EC (Translators). Am. J. Psychiatry 140(9), 1127-1133 (1983).
15. Cassano GB, Mula M, Rucci P et al. The structure of lifetime manichypomanic spectrum. J. Affect. Disord. 112(1-3), 59-70 (2009).
16. Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J. Neurol. Neurosurg. Psychiatry 75(10), 1376-1381 (2004).
17. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am. J. Psychiatry 155(1), 30-35 (1998).
18. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol. Psychiatry 48(6), 445-457 (2000).
19. Amann B, Grunze H. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia 46(Suppl. 4), 26-30 (2005).
20. Mazza M, Di Nicola M, Della Marca G, Janiri L, Bria P, Mazza S. Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions. Neuroscientist 13(4), 392-404 (2007).
21. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 25(3), 295-330 (1969).
22. Post RM. Neurobiology of seizures and behavioral abnormalities. Epilepsia 45(Suppl. 2), 5-14 (2004).
23. Post RM, Uhde TW, Putnam FW, Ballenger JC, Berrettini WH. Kindling and carbamazepine in affective illness. J. Nerv. Ment. Dis. 170(12), 717-731 (1982).
24. Morimoto K, Sato H, Yamamoto Y, Watanabe T, Suwaki H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 38(9), 966-974 (1997).
25. Post RM, Weiss SR. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 13(1), 33-60 (1996).
26. Kupka R, Post R. Kindling as a model for affective disorders. In: Seizures, Affective Disorders and Anticonvulsant Drugs. Trimble M, Schmitz B (Eds). Clarius Press, Guilford, UK (2002).
27. Maes M, Verkerk R, Vandoolaeghe E et al. Serotonin-immune interactions in major depression: lower serum tryptophan as a marker of an immune-inflammatory response. Eur. Arch. Psychiatry Clin. Neurosci. 247(3), 154-161 (1997).
28. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J. Neurochem. 89(4), 834-843 (2004).
29. Petty F. Plasma concentrations of γ-aminobutyric acid (GABA) and mood disorders: a blood test for manic depressive disease? Clin. Chem. 40(2), 296-302 (1994).
30. Guidotti A, Auta J, Davis JM et al. Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 57(11), 1061-1069 (2000).
31. Post RM, Speer AM, Hough CJ, Xing G. Neurobiology of bipolar illness: implications for future study and therapeutics. Ann. Clin. Psychiatry 15(2), 85-94 (2003).
32. Speckmann EJ, Straub H, Köhling R. Contribution of calcium ions to the generation of epileptic activity and antiepileptic calcium antagonism. Neuropsychobiology 27(3), 122-126 (1993).
33. Dubovsky SL, Thomas M, Hijazi A, Murphy J. Intracellular calcium signaling in peripheral cells of patients with bipolar affective disorder. Eur. Arch. Psychiatry Clin. Neurosci. 243(5), 229-234 (1994).
34. Kraepelin E. Psychiatrie. Band 3. Johann Ambrosius Barth, Leipzig, Germany, (1923).
35. Bleuler E. Lehrbuch der Psychiatrie. 8th Edition. Springer-Verlag, Berlin, Germany, (1949).
36. Gastaut H, Morin G, Lesevre N. Etude du comportement des epileptiques psychomoteurs dans l'intervalle de leurs crises: les troubles de l'activitè globale et de la sociabilitè. Ann. Med. Psychol. (Paris) 113, 1-27 (1955).
37. Blumer D. Dysphoric disorders and paroxysmal affects: recognition and treatment of epilepsy-related psychiatric disorders. Harv. Rev. Psychiatry 8(1), 8-17 (2000). •• Seminal paper on the interictal dysphoric disorder of epilepsy.
38. Himmelhoch JM. Major mood disorders related to epileptic changes. In: Psychiatric aspects of epilepsy. Blumer D (Ed). American Psychiatric Press, Washington DC, USA, 271-294 (1984)
39. Kanner AM. Psychiatric comorbidity in patients with developmental disorders and epilepsy: a practical approach to its diagnosis and treatment. Epilepsy Behav. 3(6 Suppl. 1), 7-13 (2002).
40. Möller HJ Curtis VA The bipolar spectrum: diagnostic and pharmacologic considerations. Expert Rev. Neurother. 4(6 Suppl. 2), S3-S8 (2004).
41. Benazzi F. Is there a continuity between bipolar and depressive disorders? Psychother. Psychosom. 76(2), 70-76 (2007).
42. Hirschfeld RM, Holzer C, Calabrese JR et al. Validity of the mood disorder questionnaire: a general population study. Am. J. Psychiatry 160(1), 178-180. (2003).
43. Akiskal HS, Pinto O The evolving bipolar spectrum. Prototypes I, II, III, and IV. Psychiatr. Clin. North Am. 22(3), 517-534, (1999).
44. Blumer D, Montouris G, Davies K. The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy. Epilepsy Behav. 5, 826-840 (2004).
45. Mula M, Schmitz B, Jauch R et al. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav. 13(4), 658-661 (2008). •• The only available study to date addressing the relationships between bipolar disorders and peri-ictal symptoms.
46. Akiskal HS. Temperament and mood disorders. Harv. Ment. Health Lett. 16(8), 5-6 (2000).
47. Kanner AM. Peri-ictal psychiatric phenomena: clinical characteristics and implications of past and future psychiatric disorders. In: Psychiatric Issues in Epilepsy: a Practical Guide to Diagnosis and Treatment (2nd Edition). Ettinger A, Kanner AM (Eds). Lippincott, Wiliams & Wilkins, Philadelphia, PA, USA, 321-345 (2007).
48. Kanner. Do peri-ictal psychiatric symptoms account for the differences between depressive disorders in patients with and without epilepsy? In: Psychiatric controversies in epilepsy. Kanner AM, Schachter S (Eds). Elsevier, New York, NY, USA, 201-209 (2008).
49. Blanchet P, Frommer GP. Mood change preceding epileptic seizures. J. Nerv. Ment. Dis. 174(8), 471-476 (1986).
50. Scaramelli A, Braga P, Avellanal A et al. Prodromal symptoms in epileptic patients: clinical characterization of the pre-ictal phase. Seizure 18(4), 246-250 (2009).
51. Fisher RS, Schachter SC. The postictal state: a neglected entity in the management of epilepsy. Epilepsy Behav. 1(1), 52-59 (2000).
52. Boylan LS. Peri-ictal behavioral and cognitive changes. Epilepsy Behav. 3(1), 16-26 (2002).
53. Kanner AM, Soto A, Gross-Kanner H. Prevalence and clinical characteristics of postictal psychiatric symptoms in partial epilepsy. Neurology 62, 708-713 (2004). •• The only detailed account of post-ictal psychiatric symptoms in epilepsy.
54. Nishida T, Kudo T, Inoue Y et al. Postictal mania versus postictal psychosis: differences in clinical features, epileptogenic zone, and brain functional changes during postictal period. Epilepsia 47(12), 2104-2114 (2006).
55. Kanemoto K. Postictal psychoses, revisited. In: The Neuropsychiatry of Epilepsy. Trimble M, Schmitz B (Eds). Cambridge University Press, Cambridge, UK, 117-131 (2002).
56. Landolt H. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lectures on Epilepsy. Lorentz de Haas AM (Ed.). Elsevier, Amsterdam, The Netherlands, 91-133 (1958).
57. Wolf P. The clinical syndromes of forced normalization. Folia Psychiatr. Neurol. Jpn 38, 187-192 (1984).
58. Monaco F, Mula M. Phenytoin and other hydantoins. Clinical efficacy and use in psychiatric disorders. In: Antiepileptic Drugs (5th Edition). Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott, Wiliams & Wilkins, Philadelphia, PA, USA, 600-604 (2002).
59. Ettinger AB. Psychotropic effects of antiepileptic drugs. Neurology 67(11), 1916-1925 (2006).
60. Ceron-Litvoc D, Soares BG, Geddes J, Litvoc J, de Lima MS. Comparison of carbamazepine and lithium in treatment of bipolar disorder: a systematic review of randomized controlled trials. Hum. Psychopharmacol. 24(1),19-28 (2009).
61. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord. 6, 57-75 (2004).
62. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Bipolar Disorder (Revision). Am. J. Psychiatry 159(Suppl. 4), 1-50 (2002).
63. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 17(2), 149-173 (2003).
64. Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin. Drug Metab. Toxicol. 5(5), 539-551 (2009).
65. Mula M, Cavanna AE, Monaco F. Psychopharmacology of topiramate: from epilepsy to bipolar disorder. Neuropsychiatr. Dis. Treat. 2(4), 475-488 (2006).
66. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J. Clin. Psychopharmacol. 27(3), 263-272 (2007).
67. Krauthammer C, Klerman GL. Secondary mania: manic syndrome associated with antecedent physical illness or drugs. Arch. Gen. Psychiatry 30, 74-79 (1978).
68. Mula M, Monaco F. Antiepileptic drug-induced mania in patients with epilepsy: what do we know? Epilepsy Behav. 9(2), 265-267. (2006).
69. Kugoh T, Watanabe M, Obayashi K, Fujioka K, Hosokawa K. Two cases with epilepsy who manifested manic-depressive symptoms under barbiturates treatment. J. Psychiatry Neurol. 45(2), 437-438 (1991).
70. Patten SB, Klein GM, Lussier C, Sawa R. Organic mania induced by phenytoin: a case report. Can. J. Psychiatry 34(8), 827-828 (1989).
71. Reiss Al, O'Donnell DJ. Carbamazepineinduced mania in two children: case report. J. Clin. Psychiatry 45(6), 272-274 (1984).
72. Drake ME Jr, Peruzzi WT. Manic state with carbamazepine therapy of seizure. J. Nat. Med. Assoc. 78(11), 1105-1107 (1986).
73. Scull DA, Trimble MR. Mania precipitated by carbamazepine withdrawal. Br. J. Psychiatry 167(5), 698 (1995).
74. Sastre-Garau P, Thomas P, Beaussart M, Goudemand M. Subsequent manic onset caused by association of vigabatrinclomipramine. Encephale 4, 51-52 (1993).
75. Short C, Cooke L. Hypomania induced by gabapentin. Br. J. Psychiatry 166 (5), 679-680 (1995).
76. Hill RR, Stagno SJ, Tesar GE. Secondary mania associated with the use of felbamate. Psychosomatics 36(4), 404-406 (1995).
77. Schlatter FJ, Soutullo CA, Cervera-Enguix S. First break mania associated with topiramate treatment. J. Clin. Psychopharmacol. 21(4), 464-466 (2001).
78. Jochum T, Bar KJ, Sauer H. Topiramate induced manic episode. J. Neurol. Neurosurg. Psychiatry 73(2), 208-209 (2002).
79. Charles CL, Stoesz L, Tollefson G. Zonisamide-induced mania. Psychosomatics 31(2), 214-217 (1990).
80. Ozawa K, Kobayashi K, Noda S, Iyo M. Zonisamide-induced depression and mania in patients with epilepsy. J. Clin. Psychopharmacol. 24(1), 110-111 (2004).
81. Klein JP, Jean-Baptiste M, Thompson JL, Bowers MB Jr. A case of hypomania following vagus nerve stimulation for refractory epilepsy. J. Clin. Psychiatry 64(4), 485 (2003).
82. Barry JJ, Ettinger AB, Friel P et al. Advisory Group of the Epilepsy Foundation as part of its Mood Disorder. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 13(Suppl. 1), S1-29 (2008). •• The only available proposal of guidelines for the treatment of mood disorders in patients with epilepsy.
83. Bauer M, Beaulieu S, Dunner DL, Lafer B, Kupka R. Rapid cycling bipolar disorder - diagnostic concepts. Bipolar Disord. 10(1 Pt 2), 153-162 (2008).
84. Grunze H, Kasper S, Goodwin G et al. World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J. Biol. Psychiatry 3(3), 115-124 (2002).
85. Trimble MR, Krishnamoorthy ES. The use of ECT in neuropsychiatric disorders. In: The ECT handbook (2nd Edition). Scott AIF (Ed.). The Royal College of Psychiatrists, London, UK, 47-56 (2005).
86. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int. J. Neuropsychopharmacol. 11(7), 999-1029 (2008).
87. Azorin JM, Kaladjian A. An update on the treatment of bipolar depression. Expert Opin. Pharmacother. 10(2), 161-172 (2009).
88. Gao K, Kemp DE, Ganocy SJ, Gajwani P, Xia G, Calabrese JR. Antipsychoticinduced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28(2), 203-209 (2008).
89. Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: haematological and thyroid effects. Am. J. Psychiatry 147, 615-620 (1990).
90. Vieweg V, Shutty M, Hundley P, Leadbetter R. Combined treatment with lithium and carbamazepine. Am. J. Psychiatry 148, 398-399 (1991).
91. Hensiek A, Trimble MR. Relevance of new psychotropic drugs for the neurologist. J. Neurol. Neurosurg. Psychiatry 72, 281-285 (2002).
92. Freeman MP, Stool AL. Mood stabilizer combinations: a review of safety and efficacy. Am. J. Psychiatry 155, 12-21 (1998).
93. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br. J. Clin. Pharmacol. 50, 193-195 (2000).
94. Abraham G, Owen J. Topiramate can cause lithium toxicity. J. Clin. Psychopharmacol. 24, 565-567 (2004).
95. Erwin CV, Gerber CJ, Morrison SD, James JF. Lithium carbonate and convulsive disorders. Arch. Gen. Psychiatry 28, 646-648 (1973).
96. Jus A, Villenueve A, Gautier J et al. Influence of lithium carbonate on patients with temporal epilepsy. Can. Psychiatr. Assoc. J. 18, 77-78 (1973).
97. Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J. Biol. Psychiatry 5(3), 120-135 (2004).
98. Suppes T, Dennehy EB, Hirschfeld RM et al. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66(7), 870-886 (2005).
99. Koch-Stoecker S. Antipsychotic drugs and epilepsy: indications and treatment guidelines. Epilepsia 43(Suppl. 2), 19-24 (2002).
100. Schmitz B. Antidepressant drugs: indications and guidelines for use in epilepsy. Epilepsia 43(Suppl. 2), 13-18 (2002).
101. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol. Psychiatry 62, 345-354 (2007). •• Meta-analysis of the US FDA data on seizure occurrence during regulatory trials for antidepressant or antipsychotic drugs.
102. Dailey JW, Naritoku DK. Antidepressants and seizures: clinical anecdotes overshadow neuroscience. Biochem. Pharmacol. 52, 1323-1329 (1996).
103. Jobe PC, Browning RS. The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav. 7, 602-619